JP2023509849A5 - - Google Patents

Info

Publication number
JP2023509849A5
JP2023509849A5 JP2022535595A JP2022535595A JP2023509849A5 JP 2023509849 A5 JP2023509849 A5 JP 2023509849A5 JP 2022535595 A JP2022535595 A JP 2022535595A JP 2022535595 A JP2022535595 A JP 2022535595A JP 2023509849 A5 JP2023509849 A5 JP 2023509849A5
Authority
JP
Japan
Prior art keywords
neutrophils
treating cancer
cancer
reference standard
unsuitable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022535595A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509849A (ja
Filing date
Publication date
Priority claimed from GBGB1918313.6A external-priority patent/GB201918313D0/en
Application filed filed Critical
Publication of JP2023509849A publication Critical patent/JP2023509849A/ja
Publication of JP2023509849A5 publication Critical patent/JP2023509849A5/ja
Pending legal-status Critical Current

Links

JP2022535595A 2019-12-12 2020-12-11 癌を処置するための細胞 Pending JP2023509849A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1918313.6 2019-12-12
GBGB1918313.6A GB201918313D0 (en) 2019-12-12 2019-12-12 Cells for treating cancer
PCT/GB2020/053199 WO2021116713A1 (en) 2019-12-12 2020-12-11 Cells for treating cancer

Publications (2)

Publication Number Publication Date
JP2023509849A JP2023509849A (ja) 2023-03-10
JP2023509849A5 true JP2023509849A5 (enExample) 2023-12-12

Family

ID=69186690

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535595A Pending JP2023509849A (ja) 2019-12-12 2020-12-11 癌を処置するための細胞

Country Status (10)

Country Link
US (1) US20230203441A1 (enExample)
EP (1) EP4073509A1 (enExample)
JP (1) JP2023509849A (enExample)
CN (1) CN115136005A (enExample)
AU (1) AU2020402167A1 (enExample)
BR (1) BR112022011349A2 (enExample)
CA (1) CA3173535A1 (enExample)
GB (1) GB201918313D0 (enExample)
IL (1) IL293740A (enExample)
WO (1) WO2021116713A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201618106D0 (en) 2016-10-26 2016-12-07 Lift Biosciences Ltd Cancer-killing cells
WO2024189333A1 (en) 2023-03-10 2024-09-19 Lift Biosciences Ltd Immunomodulatory cells and compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US9199028B2 (en) * 2010-01-15 2015-12-01 Memorial Sloan-Kettering Cancer Center Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients
WO2016020530A1 (en) * 2014-08-07 2016-02-11 Reponex Pharmaceuticals Aps Compositions for the treatment of periotonitis

Similar Documents

Publication Publication Date Title
Wang et al. Robust differentiation of human pluripotent stem cells into endothelial cells via temporal modulation of ETV2 with modified mRNA
Schneider et al. Rps14 haploinsufficiency causes a block in erythroid differentiation mediated by S100A8 and S100A9
Bakri et al. Balance of MafB and PU. 1 specifies alternative macrophage or dendritic cell fate
Chapellier et al. Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response
FI3835415T3 (fi) Menetelmä cd3-positiivisen solun tuottamiseksi
de Haar et al. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation
JP2023509849A5 (enExample)
Teo et al. Tumor-associated neutrophils attenuate the immunosensitivity of hepatocellular carcinoma
Zhang et al. Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells
Zhan et al. Single‐cell sequencing combined with spatial transcriptomics reveals that the IRF7 gene in M1 macrophages inhibits the occurrence of pancreatic cancer by regulating lipid metabolism‐related mechanisms
Nedelkovska et al. Follicular lymphoma tregs have a distinct transcription profile impacting their migration and retention in the malignant lymph node
JP7025524B2 (ja) 非動員末梢血を利用した不均一性造血幹細胞・前駆細胞の製造方法
Belay et al. Human cord blood and bone marrow CD34+ cells generate macrophages that support erythroid islands
Yoshikawa et al. Characterization of CD133+ parenchymal cells in the liver: Histology and culture
Signoretto et al. Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis
Zhang et al. IL17A/F secreted by ASCT2-overexpression ovarian cancer cells contributes to immune escape through the suppression of natural killer (NK) cells cytotoxicity by the activation of c-JUN/PTGS2 pathway
JP2021500081A5 (enExample)
Meng et al. Plac1+ Tumor Cell‐Treg Interplay Supports Tumorigenesis and Progression of Head and Neck Cancer
CN119372160A (zh) 源自ido1基因的hla-a*11:01肾细胞癌肿瘤抗原短肽
Hernandez‐Fernaud et al. Quantitative mass spectrometry‐based proteomics in angiogenesis
CN102876632B (zh) 人nk/t细胞系
CN107236709B (zh) 来源于肺转移灶的高转移人卵巢癌细胞系及其建立和应用
CN112451662A (zh) 一种gli蛋白抑制剂及其应用
CN113493767A (zh) 利用人多潜能干细胞体外制备嗜酸性粒细胞
Al-Khalaf et al. Interleukin-8 dedifferentiates primary human luminal cells to multipotent stem cells